Abstract

  Systemic lupus erythematosus (SLE), myasthenia gravis (MG) and polymyositis (PM) are three autoimmune diseases that have upper incidence in young women, SLE, MG and PM are three different clinical syndromes which can be coexist or precede each other’s, although their occurrence and presence in the same patients are uncommon and rare. The aims of this study are to report the first association of the three immunological diseases in a single patient. Here we report a 36 years old lady with confirmed SLE and on hydroxychloroquine (HCQ) and tapered steroid, 20 months later developed MG, then Creatine Kinase (CK), nerve conduction studies (NCS) and electromyography (EMG) relieved the diagnosis of PM. The patient received four dosages of intravenous immunoglobulin but developed allergic reactions, then rituximab been administrated and all the complained symptoms resolved and the patient returned to her normal daily activities.

Keywords: Systemic Lupus Erythematosus; Myasthenia Gravis; Polymyositis; Rituximab

References

1. Nagarajan M., et al. “Systemic Lupus Erythematosus and Myasthenia Gravis: A Rare Association”. Indian Journal of Nephrology 29.1 (2019): 62-64.
2. Zhang B., et al. “Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis”. Archives of Neurology 69.4 (2012): 445-51.
3. Mozo L., et al. “A case of polymyositis associated with the presence of anti-proliferating cell nuclear antigen antibodies, a marker typically considered SLE specific”. Lupus 19.8 (2010): 1002-1003.
4. Pons-Estel GJ., et al. “Understanding the epidemiology and progression of systemic lupus erythematosus”. Seminars in Arthritis and Rheumatism 2010 39.2 (2010): 257-268.
5. Chakravarty EF., et al. “Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data”. Arthritis and rheumatism 56.6 (2007): 2092-2094.
6. Tiffin N., et al. “Lupus in Africa: Can we dispel the myths and face the challenges?” Lupus (2013): 23.
7. Kumar K., et al. “Challenges of ethnicity in SLE”. Best Practice and Research Clinical Rheumatology 23.4 (2009): 549-561.
8. Elagib E., et al. “Catastrophic Antiphospholipid Syndrome in Combination with SLE Treated by Rituximab: A Case Report and Literature Review”. Lupus: Open Access 4 (2019): 137.
9. Sîrbu E., et al. “Systemic lupus erythematosus followed by myasthenia gravis: a rare association”. Central European Journal of Medicine 8.6 (2013): 799-802.
10. McDonagh JE and Isenberg DA. “Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus”. Annals of the Rheumatic Diseases 59.3 (2000): 230-232.
11. Castrejón I., et al. “Association between myasthaenia gravis and systemic lupus erythematosus: three case reports and review of the literature”. Scandinavian Journal of Rheumatology 40 (2011): 486-490.
12. Song J., et al. “Meta-Analysis of Polymyositis and Dermatomyositis Microarray Data Reveals Novel Genetic Biomarkers”. Genes 10.11 (2019).
13. Pasnoor M., et al. “Diagnosis of Myasthenia Gravis”. Neurologic clinics 36 (2018): 261-274.
14. Mustafa MS., et al. “Delayed Diagnosis of Atypical Presentation of Myasthenia Gravis”. European journal of Case Reports in Internal Medicine 5.2 (2018): 000785.
15. Hostmann A., et al. “Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus”. Lupus 17.12 (2008): 1064-1069.
16. Kigawa N., et al. “Development of myasthenia gravis in systemic lupus erythematosus”. European Journal of Case Reports in Internal Medicine 1 (2014).
17. Banica L., et al. “Quantification and molecular characterization of regulatory T cells in connective tissue diseases”. Autoimmunity 42.1 (2009): 41-49.
18. Casado E., et al. “Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients”. Annals of the Rheumatic Diseases 65 (2006): 385-390.
19. Mai W., et al. “Up-regulated expression of Fas antigen in peripheral T cell subsets in patients with myasthenia gravis”. Clinical and Investigative Medicine 35.5 (2012): E294.
20. Mahmoud ZIT., et al. “The role of hydroxychloroquine as monotherapy in managing early undifferentiated arthritis: a prospective hospital-based study”. Global Journal of Public Health Medicine 1 (2019): 52-62.
21. Ungprasert P., et al. “Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in Asian population”. ISRN Rheumatology (2013).
22. Tomasová Studýnková J., et al. “The role of MRI in the assessment of polymyositis and dermatomyositis” (2007).
23. Volochayev R., et al. “Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups”. The Open Rheumatology Journal 6 (2012): 54-63.
24. Yang F., et al. “Electrophysiological and clinical examination of polymyositis: a retrospective analysis”. The American Journal of the Medical Sciences 348.2 (2014): 162-166.
25. Garton MJ and Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases”. British Journal of Rheumatology 36 (1997): 1067-1074.
26. Kilani B., et al. “Association of systemic lupus erythematosus and dermatopolymyositis”. La Tunisie medicale 83 (2005): 230-232.
27. Rostic G., et al. “Systemic lupus erythematosus and dermatomyositis--case report”. Srpski arhiv za celokupno lekarstvo 133 (2005): 137-140. 
28. Maazoun F., et al. “Systemic lupus erythematosusmyositis overlap syndrome: report of 6 cases”. Clinics and Practice 1.4 (2011): e89.
29. Liang Y., et al. “Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study”. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 23 (2017): 2543-2549.
30. Levine TD. “Rituximab in the treatment of dermatomyositis: an open-label pilot study”. Arthritis and Rheumatism 52.2 (2005): 601-607.

Citation

Citation: Abdelkareem A Ahmed., et al. “A Case of Myasthenia Gravis and Polymyositis developed in Systemic Lupus Erythematosus Patient and Managed by Rituximab”. Acta Scientific Women's Health 2.3 (2020): 15-18.

Copyright

Copyright: © 2020 Abdelkareem A Ahmed., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.